Anatara Lifesciences Embarks on Stage 2 of GaRP Trial for Treatment of Irritable Bowel Syndrome

Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS).

Small CapsJun 10 19:20 ET

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%

Anatara Lifesciences (ASX:ANR) secured firm commitments to raise AU$1 million, before costs, via the placement of 25 million new shares, the company said in a Wednesday filing with the Australian bour

MT NewswiresApr 30 23:25 ET

Anatara Lifesciences Opens GaRP Therapy Trial Extension to Treat Irritable Bowel Syndrome

Anatara Lifesciences (ASX: ANR) is inviting members of the public to register their interest in Stage 2 of a pivotal Phase II Australian clinical trial of their gastrointestinal reprogramming (GaRP) product in the treatment of irritable bowel syndrome (IBS).

Small CapsApr 8 22:59 ET

Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial

Anatara Lifesciences (ASX:ANR) has begun recruiting patients for the second stage of its irritable bowel syndrome trial after receiving final ethics approvals, according to a Tuesday filing with the A

MT NewswiresApr 8 22:42 ET

Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer

Anatara Lifesciences (ASX:ANR) raised about AU$955,637 via a 2-for-5 entitlement offer at AU$0.022 per share. Funds raised will be for the second stage of the GaRP-IBS trial, according to a Thursday n

MT NewswiresDec 8, 2023 03:17 ET

Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial

Anatara Lifesciences (ASX:ANR) said it has met the study objectives of stage I of its gastrointestinal reprogramming (GaRP) medication trial, for irritable bowel syndrome (IBS). The Data Safety Monito

MT NewswiresSep 28, 2023 06:57 ET